|Articles|November 20, 2017
Industry-Sponsored Phase III Clinical Trial Activity
Author(s)Harold E. Glass, PhD
David Akirtava
David Akirtava
Published data indicate the size and complexity of these Phase III studies has hardly changed over the last few years.
Advertisement
R&D spending, according to a number of sources, continues to grow as biopharmaceutical solutions become integral to a wider range of medical maladies. Phase III clinical trials represent the critical data foundation in the new drug approval process for regulatory authorities around the world. Published data indicate the size and complexity of these Phase III studies has hardly changed over the last few years. Despite some assertions about a growing number of clinical trials, there are no data, which can be verified by third parties, supporting these assertions. In fact, one of the most widely accepted sources of data on clinical trials, ClinicalTrials.gov, points to an opposite conclusion.
ClinicalTrials.gov is a federal database, mandated since 2007 for all organizations conducting studies under FDA auspices. Missing data for any of the variables is often close to zero, and rarely exceeds three percent. ClinicalTrials.gov has become a widely used tool by drug development professionals and a frequently cited data source for research publications.
The randomized clinical trial (RCT) model has come under stress as the requirements of conducting RCTs became more demanding. As therapies become more targeted though, the financial calculus might very well make these RCTs even more problematic. Yet to date, the number of industry sponsored Phase III clinical trials continues unchanged. The slight drop in the 2016 reflects a slight lag in reporting.
Number of Industry Sponsored Phase III Opened in Each Year
Year
2014
2015
2016
Worldwide
892
902
808
United States
505
561
487
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Reimagining Clinical Trials for Remote Populations
August 29th 2025
- How Research Sites Balance Funding Cuts and Efficiency Pressures
August 26th 2025
- How Flexible Site Models Can Cut Recruitment Costs and Timelines
August 21st 2025
- Overcoming Budget Barriers to Patient-Centric Trial Models
August 20th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5